Technological Advances in Anti-hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation.

Xuexue Pan, Rongfei Yu, Jingyi Wu, Wenkai Li, Rongyue Huang et al.

Review Aesthetic plastic surgery 2025 2 citations

<\/script>\n

`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'pmid\u003D40790388'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Study Design

Study Type: Review

Intervention: Technological Advances in Anti-hair Loss and Hair Regrowth Cosmeceuticals: Mechanistic Breakthroughs and Industrial Prospects Driven by Multidisciplinary Collaborative Innovation. None
Comparator: Placebo
Effect Direction: Mixed
Risk of Bias: Unclear

Abstract

In light of the escalating global prevalence of hair loss, there is an imperative to explore strategies for the prevention and promotion of hair growth. This article reviews the current situation, challenges, innovations, and prospects of cosmetics that promote anti-hair loss and hair growth. Firstly, the physiological and pathological mechanisms of hair loss, including androgenetic alopecia, telogen effluvium, and alopecia areata, as well as the influence of genetic, environmental, and lifestyle factors, are explored. Subsequently, a comprehensive analysis of the predominant product categories and ingredients currently available on the market was conducted, encompassing minoxidil, finasteride, plant extracts, growth factors, and peptides. Building on this, this article further explores the challenges of anti-hair loss and hair growth promotion cosmetics, including effectiveness and safety, consumer acceptance, and the complexity of regulations and standards. This was followed by an introduction to innovations in the field, such as gene therapy, stem cell technology, and microneedling, as well as advanced delivery systems and personalized care options. Finally, this paper looks forward to future technologies' development trends and market prospects. It emphasizes the importance of multidisciplinary cooperation, including the combination of medicine and cosmetology and the integration of biotechnology and materials science. By synthesizing extant research and delineating prospective research directions, this paper establishes an indispensable reference point for the research and development of cosmetics designed to promote hair growth and prevent hair loss.Level of Evidence V This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

Full Text

PDF

Loading PDF...

Figures

Fig. 1

Overview of the global hair loss landscape and market trends driving demand for anti-hair loss cosmeceuticals.

diagram

Fig. 2

Mechanistic pathways targeted by cosmeceutical ingredients for hair loss prevention, including DHT inhibition, microcirculation enhancement, and follicle stem cell activation.

diagram

Fig. 3

Classification of active ingredients used in anti-hair loss cosmeceuticals by their biological targets and mechanisms of action.

diagram

Fig. 4

Technological advances in delivery systems for hair regrowth cosmeceuticals, including nanoparticles, microneedles, and liposomal formulations.

diagram

Fig. 5

Comparison of clinical efficacy data across different cosmeceutical active ingredients for promoting hair regrowth.

chart

Fig. 6

Illustration of the hair follicle cycle phases and how various cosmeceutical interventions target specific stages to prevent loss and promote growth.

diagram

Fig. 7

Multidisciplinary innovation framework showing the convergence of biotechnology, materials science, and dermatology in developing next-generation hair regrowth products.

diagram

Fig. 8

Summary of clinical trial designs and regulatory considerations for cosmeceutical hair regrowth products.

diagram

Fig. 9

Analysis of industrial prospects and patent landscape for anti-hair loss cosmeceutical technologies.

chart

Fig. 10

Scalp microbiome interactions and their relevance to cosmeceutical approaches for hair loss management.

diagram

Fig. 11

Emerging plant-derived and biotechnology-sourced active compounds under investigation for hair growth promotion.

diagram

Fig. 12

In vitro and in vivo evaluation strategies for assessing the efficacy of anti-hair loss cosmeceutical formulations.

diagram

Fig. 13

Consumer preference and market segmentation analysis for hair regrowth cosmeceutical products.

chart

Fig. 14

Future directions and research gaps in the development of anti-hair loss cosmeceuticals driven by multidisciplinary collaborative innovation.

diagram

Tables

Table 1

Parameters	Traditional Chinese Medicine (TCM) methods	Modern biotechnology methods	Literature support
Randomized controlled trial evidence	Limited and questionable in quality: • The rate of phase III RCTs is only 18% (FDA data) [141–143], and only 3% of RCTs in Chinese journals meet the standards of randomization + allocation concealment + blinding [141, 144] • 100% of injection studies did not report blinding or conflicts of interest [145, 146] • The average protocol reporting compliance rate from 2020 to 2023 was only 35.4%[147]	Systematization and high quality: • 92% of synthetic drugs complete phase III RCTs (FDA) [141, 148] • Strict implementation of the CONSORT statement (blinding > 95%) [141, 147]	[141, 142]
Standardization	Significant batch variation: • Individualized prescriptions have no standard components/dosages (dominated by physicians’ experience) [141, 149, 150] • Large quality fluctuations in Chinese patent medicines (e.g., unquantified components in injections) [145, 150] • Only 20.4% of formula granule studies formally report components [147, 148]	Strict quality control: • Purity of active compounds > 98% • Production processes comply with GMP	[141, 145, 147]
Regulatory supervision	Fragmentation and reform coexist: • The EU THMPD requires a 30-year history of use (including 15 years of EU application) [150] • China’s NMPA promotes ten priority areas: real-world evidence (RWE), evaluation standards for classic formulas [150] • Dietary supplements account for > 70% in the United States	Global unified framework: • IND-NDA pathway of FDA/EMA [145, 151] • ICH guidelines standardize transnational approval	[145, 150, 151]
Adverse event reporting	Voluntary system deficiencies: • FAERS reporting rate < 5% (initial data) [145, 151] • 78% of injection studies did not report safety data [145, 146] • RCTs on severe pneumonia ignored TCM syndrome differentiation-related adverse reactions [149, 151]	Mandatory pharmacovigilance: • Post-marketing surveillance coverage rate > 90% • Safety data updated in real-time (June 05, 2025) (EMA) [151]	[145, 146]
Mechanism clarity	Progress in multi-target verification: • Network pharmacology integrates eRCT and pRCT [152, 153] • Hypertension treatment shows pleiotropy (blood pressure reduction + target organ protection) [154, 155] • However, > 85% of RCTs do not explain the mechanism of action [149, 156, 157]	Single-target dominance: • High mechanism predictability (e.g., 5α-reductase inhibition) • Target verification rate > 95%	[152, 154, 156]
Supplementary explanation	Potential and challenges coexist: • Clinical value: Adjuvant treatment of severe pneumonia reduces mortality (RR = 0.82) [151] and the improvement rate of hypertensive target organ damage > 50% [154, 155] • Bottlenecks: The reporting quality of acupuncture/moxibustion is better than that of drugs (compliance rate 50.3% vs. 20.4%) [147]	Evidence-based advantages: • Standardized research and development cycle (8–12 years on average) [148] • Incorporation of cost-benefit analysis into decision-making (e.g., NICE guidelines) [152]	[147, 151]